An experimental daily pill, daraxonrasib, helped patients with advanced pancreatic cancer live longer than patients receiving standard chemotherapy in a 500-person international trial presented Sunday at the American Society of Clinical Oncology annual meeting in Chicago. The study enrolled patients in North America, Europe and Asia whose pancreatic cancer had spread to other organs and who had received prior treatment. Median overall survival was 13.2 months among patients assigned daraxonra...

Read the original article